Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

Scott Randall Plotkin, M.D.,Ph.D.

Co-Author

This page shows the publications co-authored by Scott Plotkin and Vanessa Merker.
Connection Strength

6.855
  1. Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018 Aug 29; 18(1):668.
    View in: PubMed
    Score: 0.810
  2. Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
    View in: PubMed
    Score: 0.693
  3. Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015 Mar; 103(3):761-8.e1.
    View in: PubMed
    Score: 0.628
  4. Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. . 2014 Jun; 164A(6):1431-7.
    View in: PubMed
    Score: 0.596
  5. Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22.
    View in: PubMed
    Score: 0.534
  6. Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS. Neurology. 2021 08 17; 97(7 Suppl 1):S4-S14.
    View in: PubMed
    Score: 0.247
  7. The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61.
    View in: PubMed
    Score: 0.240
  8. Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021 04; 104(4):808-814.
    View in: PubMed
    Score: 0.234
  9. Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018 06; 39(5):632-638.
    View in: PubMed
    Score: 0.199
  10. Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
    View in: PubMed
    Score: 0.195
  11. Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
    View in: PubMed
    Score: 0.191
  12. Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
    View in: PubMed
    Score: 0.175
  13. Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75.
    View in: PubMed
    Score: 0.171
  14. Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system. Am J Obstet Gynecol. 2015 Jul; 213(1):108-109.
    View in: PubMed
    Score: 0.158
  15. Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
    View in: PubMed
    Score: 0.158
  16. Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
    View in: PubMed
    Score: 0.157
  17. Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014 May; 39(5):e301-7.
    View in: PubMed
    Score: 0.150
  18. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1197-204.
    View in: PubMed
    Score: 0.149
  19. Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014 Jan; 35(1):e50-6.
    View in: PubMed
    Score: 0.147
  20. Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
    View in: PubMed
    Score: 0.142
  21. Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013; 8(3):e59941.
    View in: PubMed
    Score: 0.139
  22. Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem. 2013 May; 46(7-8):698-700.
    View in: PubMed
    Score: 0.136
  23. Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012 Aug; 33(6):1046-52.
    View in: PubMed
    Score: 0.133
  24. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711.
    View in: PubMed
    Score: 0.130
  25. Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S32-S41.
    View in: PubMed
    Score: 0.062
  26. First report of factors associated with satisfaction in patients with neurofibromatosis. . 2017 03; 173(3):671-677.
    View in: PubMed
    Score: 0.046
  27. First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
    View in: PubMed
    Score: 0.045
  28. Creation of an international registry to support discovery in schwannomatosis. . 2017 Feb; 173(2):407-413.
    View in: PubMed
    Score: 0.044
  29. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016 Jun; 133(6):475-80.
    View in: PubMed
    Score: 0.041
  30. The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
    View in: PubMed
    Score: 0.038
  31. Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013 Feb; 55(2):146-53.
    View in: PubMed
    Score: 0.034
  32. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2012 Aug; 41(8):917-23.
    View in: PubMed
    Score: 0.032
Connection Strength
The connection strength for co-authors is the sum of the scores for each of their shared publications.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.